Boehringer Ingelheim announced the expansion of its global Computational Innovation footprint with the launch of a new centre ...
Centre for Cellular and Molecular Platforms (C-CAMP) has signed an MoU with Imperial College London, to institute a ...
Merck, known as MSD outside of the United States and Canada, and Eisai announced results from the phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients ...
Merck, a leading science and technology company, has launched the first bio-based solvent portfolio specifically for high-performance liquid chromatography (HPLC). Manufactured using renewable ...
Supriya Lifescience Limited, a leading API manufacturer, announced the US FDA has issued an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification for its API ...
Aahwahan Foundation has distributed of 1,000 fully automated wheelchairs to underprivileged and differently-abled individuals ...
The Atal MedTech Museum & Library, a one-of-a-kind centre was inaugurated today at Andhra Pradesh MedTech Zone (AMTZ) by Hon’ble Former Vice President of India M. Venkaiah Naidu, marking a significant ...
Allurion Technologies Inc, a pioneer in metabolically healthy weight loss, announced the successful commercial treatment of its first patients in the United States - an inflection point that formally ...
Addex Therapeutics’ GABAB PAM candidate shows robust anti-tussive activity in non-human primate chronic cough model: Geneva, Switzerland Wednesday, April 22, 2026, 18:00 Hrs [IS ...
Greenspace Herbs launches Curcumin QA designed for higher absorption at lower doses: Our Bureau, Bengaluru Wednesday, April 22, 2026, 17:25 Hrs [IST] Bengaluru-based Greenspace He ...
Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...
Positive high-level results from a prespecified interim analysis of the I CAN phase III trial showed that Ultomiris (ravulizumab) met its primary endpoint, demonstrating a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results